At 10.1% CAGR, the Asia Pacific dPCR and qPCR Market is Projected to be Worth US$ 4,139.50 Million by 2030, Says Business Market Insights

According to Business Market Insights research, the Asia Pacific dPCR and qPCR market was valued at US$ 1,913.43 million in 2022 and is expected to reach US$ 4,139.50 million by 2030, registering a CAGR of 10.1% from 2022 to 2030. Increasing incidence of genetic and technological advancements in PCR technologies are among the critical factors attributed to the Asia Pacific dPCR and qPCR market expansion.

According to the National Organization's information on genetic conditions or congenital disabilities, though individual genetic disorders are rare, collectively, they comprise over 15,500 people diagnosed with genetic disorders. Furthermore, the disease is most prevalent in emerging nations such as India. Among India's tribal communities, ~18 million people are affected by sickle cell trait (SCT), and 1.4 million people are suffering from sickle cell disease (SCD). The adoption of digital PCR is improving as pathologists are trying to track the use of this technology to target various specific DNA sequences and diagnose and design various clinical tests. Digital PCR can target specific DNA sequences in just one molecule of DNA. This new tool allows researchers to isolate rare genetic mutations that are too difficult to segregate with real-time PCR. The COVID-19 outbreak had a significant effect on the polymerase chain reaction market growth. The growing demand in the clinical diagnostic market has a favorable effect on the PCR industry. Nearly all diagnostic tests use RT-PCR to test the people having symptoms of COVID-19 and were urged by healthcare experts to undergo a diagnostic test, while the authorities have not endorsed viral culture tests. The majority of biotech and pharmaceutical businesses were concentrating their efforts on research and development divisions to find novel compounds or therapy approaches for COVID-19. In February 2022, Roche added the Cobas 5800 System, a newly released molecular laboratory instrument, to its COVID-19 PCR portfolio for use in nations that accept the CE certification. These products include the cobas SARS-CoV-2 and influenza A/B tests, as well as the cobas SARS-CoV-2 qualitative test. By offering uniform performance and efficiency across low-, medium--, and high-volume molecular laboratory testing needs, these products broaden the Roche Diagnostics molecular portfolio offering. Additionally, healthcare organizations with limited space or resources can have comprehensive access owing to the new, compact Cobas 5800 System. Better testing accessibility will result from this in nations or settings where larger equipment cannot be accommodated due to a lack of resources or space. Thus, increasing incidence of genetic and infectious diseases in which dPCR and qPCR techniques can be used for diagnosis and treatments support the growth of the Asia Pacific dPCR and qPCR market.

On the contrary, high costs of PCR systems hampers the growth of Asia Pacific dPCR and qPCR market.

Based on treatment, the Asia Pacific dPCR and qPCR market is bifurcated into quantitative PCR (qPCR) and digital PCR (dPCR). The digital PCR (dPCR) segment held 71.3% share of the Asia Pacific dPCR and qPCR market in 2022, amassing US$ 1,364.51 million. It is projected to garner US$ 3,089.15 million by 2030 to expand at 10.8% CAGR during 2022-2030.

By product, the Asia Pacific dPCR and qPCR market is segmented into reagents & consumables, instruments, and software & services. The reagents & consumables segment held 63.4% share of the Asia Pacific dPCR and qPCR market in 2022, amassing US$ 1,213.30 million. It is projected to garner US$ 2,780.77 million by 2030 to expand at 10.9% CAGR during 2022-2030.

By application, the Asia Pacific dPCR and qPCR market is segmented into research application, clinical application, and forensic application. The clinical application segment held 56.0% share of the Asia Pacific dPCR and qPCR market in 2022, amassing US$ 1,072.40 million. It is projected to garner US$ 2,573.61 million by 2030 to expand at 11.6% CAGR during 2022-2030. The clinical application segment is further subsegmented into oncology testing, blood screening, infectious disease testing, and other applications.

By end user, the Asia Pacific dPCR and qPCR market is segmented into hospitals and diagnostic centers, pharmaceutical and biotechnology companies, research laboratories and academic institutes, forensic laboratories, and clinical research organizations. The hospitals and diagnostic centers segment held 56.0% share of the Asia Pacific dPCR and qPCR market in 2022, amassing US$ 1,072.40 million. It is projected to garner US$ 2,573.61 million by 2030 to expand at 11.6% CAGR during 2022-2030.

Based on country, the Asia Pacific dPCR and qPCR market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China held 24.9% share of Asia Pacific dPCR and qPCR market in 2022, amassing US$ 477.21 million. It is projected to garner US$ 1,135.54 million by 2030 to expand at 11.4% CAGR during 2022-2030.

Key players operating in the Asia Pacific dPCR and qPCR market are Abbott Laboratories, Genome Diagnostics Pvt Ltd, Thermo Fisher Scientific Inc, Takara Bio Inc, Qiagen NV, Standard BioTools Inc, Lepu Medical Technology Beijing Co Ltd, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories Inc, and Agilent Technologies Inc, among others.




Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com